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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of 
the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Egyptian Arabic language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (20.0% systemic JIA, 40.0% undifferentiated arthritis, 24.0% RF negative 
polyarthritis, 16.0% other categories) and 100 healthy children were enrolled in one paediatric rheumatology centre. The 
JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory 
psychometric performances. In conclusion, the Egyptian Arabic version of the JAMAR is a valid tool for the assessment of 
children with JIA and is suitable for use both in routine clinical practice and in clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Egyptian Arabic parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
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Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient-reported outcomes in JIA, including overall 
well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the paediatric rheumatology international trials 
organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Egyptian Arabic language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2014 to 
December 2015. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Lik-
ert response, referring to the prior month, is ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30 with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading, 
comprehending and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
S157Rheumatology International (2018) 38 (Suppl 1):S155–S161 
1 3
the second Likert assumption or equal items–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Quantitative data were reported as medians 
with 1st and 3rd quartiles and categorical data as absolute 
frequencies and percentages.
The complete Egyptian Arabic parent and patient versions 
of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Egyptian Arabic JAMAR was fully cross-culturally 
adapted with two forward and two backward translations. 
The concordance rate between the original standard Eng-
lish version of the JAMAR and the two back-translations 
was 90.8% (109/123 lines) for the parent version and 85% 
(102/120 lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the ten parents tested 
(median = 100%; range: 80–100%). Of the 120 lines in the 
patient version of the JAMAR, 118 (98.3%) lines were 
understood by at least 80% of the children (median = 100%; 
range: 60–100%). Lines 66, 67, 68 of the child version of the 
JAMAR were modified considering patients’ suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total of 
200 subjects) were enrolled at the paediatric rheumatology 
centre in Cairo.
In the 100 JIA subjects, the JIA categories were 20.0% 
with systemic JIA, 10.0% with oligoarthritis, 24.0% with RF 
negative polyarthritis, 2.0% with RF positive polyarthritis, 
2.0% with psoriatic arthritis, 2.0% with enthesitis-related 
arthritis and 40.0% with undifferentiated arthritis (Table 1).
A total of 156/200 (78.0%) subjects had the parent ver-
sion of the JAMAR completed by a parent (100 from parents 
of JIA patients and 56 from parents of healthy children). The 
JAMAR was completed by 131/156 (84.0%) mothers and 
25/156 (16.0%) fathers. The child version of the JAMAR 
was completed by 60/200 (30.0%) children age 8.3 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items 
except for item 10, whereas a reduced number of response 
choices were used for the PF items 6, 12, 13, 14 and 15. 
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
HRQoL item 10 (data not shown). The median number of 
items marked as not applicable was 0% (0–1%) for the PF 
and 1% (0–2%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 68.0% (44.0–88.0%) for the 
PF items, 31.0% (22.0–33.0%) for the HRQoL PhH items, 
and 59.0% (57.0–69.0%) for the HRQoL PsH items. The 
median ceiling effect was 6.0% (0.0–10.0%) for the PF 
items, 11.0% (10.0–20.0%) for the HRQoL PhH items, 
and 7.0% (6.0–8.0%) for the HRQoL PsH items. The 
median floor effect was 8.0% for the pain VAS, 4.0% for 
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the disease activity VAS and 0.0% for the well-being VAS. 
The median ceiling effect was 9.0% for the pain VAS, 7.0% 
for the disease activity VAS and 6.0% for the well-being 
VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 100 JIA patients
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR, erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical Health (total score ranges from 0 
to 15), PsH psychosocial Health (total score ranges from 0 to 15)
Data related to the JAMAR refers to the 100 JIA patients and to the 56 healthy subjects for whom the questionnaire has been completed by the 
parents. p values refers to the comparison of the different JIA categories or to JIA versus healthy. * p < 0.05 ** p < 0.001 # p < 0.0001
Systemic Oligoarthritis RF− polyar-
thritis
RF + polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 20 N = 10 N = 24 N = 2 N = 2 N = 2 N = 40 N = 100 N = 100
Female 10 (50%) 4 (40%) 16 (66.7%) 2 (100%) 0 (0%) 1 (50%) 14 (35%) 47 (47%) 74 (74%)#
Age at visit 8.9 (5.1–12.8) 11.7 
(8.8–13.5)
12 (9.2–13.3) 13.9 (13.7–
14.2)
16.7 (16.4–
16.9)
13.9 (13.7–
14.2)
12.3 (8–13.7) 12 (8.2–
13.6)*
11.3 (8.2–
13.2)
Age at onset 7 (3–11) 9.4 (7–12.7) 9.3 (5.8–10.5) 9.5 (9.5–9.5) 10 (10–10) 7.5 (7.5–7.5) 9.7 (4.8–12.3) 9.2 (5.3–11)
Disease duration 1.8 (0.9–3.1) 1.3 (0.8–2.2) 2.5 (1.9–3.5) 4.4 (4.2–4.6) 6.7 (6.4–6.9) 6.4 (6.1–6.6) 1.9 (0.8–3.2) 2.1 (1–3.5)*
ESR 50 (25–90) 32.5 (30–35) 40 (30–50) 38.5 (35–42) 40 (40–40) 62.5 (60–65) 27 (20–40) 35 (25–42)*
MD VAS 2 (2–3.5) 1.5 (1–2) 3 (2–3.5) 2 (2–2) 5 (5–5) 8.8 (8.5–9) 2 (1–2) 2 (1.3–3)*
No. swollen joints 2 (0.5–7) 0 (0–2) 2 (1–4) 6 (0–12) 2 (2–2) 0 (0–0) 1 (0–2) 2 (0–3)*
No. joints with 
pain
2 (1–6.5) 2 (2–4) 6 (3.5–12) 8 (8–8) 16 (16–16) 32.5 (32–33) 2 (2–4) 3.5 (2–7)**
No. joints with 
LOM
1.5 (0.5–3) 2 (1–2) 2 (0–7) 8 (8–8) 22 (22–22) 10 (10–10) 0 (0–1) 1 (0–4)**
No. active joints 4 (2–8) 2 (2–2) 4 (3–5) 10 (8–12) 4 (4–4) 10 (10–10) 1 (1–2) 2 (1–4)**
Active systemic 
features
13 (65%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (12.5%) 18 (18%)*
ANA status 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Uveitis 2 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (100%) 2 (5%) 6 (6%)
PF total score 10 (4–14) 9 (7–12) 7 (5–11.5) 1 (1–1) 29 (29–29) 21 (21–21) 5 (3–9) 6.5 (4–12)* 0 (0–0)#
Pain VAS 4.5 (3–5.3) 6 (5–7) 7.5 (5–9) 5 (5–5) 7 (7–7) 10 (10–10) 5 (2.5–7.5) 5 (4–8)* 0 (0–0)#
Disease activity 
VAS
3.8 (3–5) 5 (4–5) 5.5 (5–8.5) 5 (5–5) 8 (8–8) 10 (10–10) 5 (3–5) 5 (3.3–5)**
Well-being VAS 5 (4–5) 5 (5–8) 5.5 (5–7) 2 (2–2) 9 (9–9) 10 (10–10) 5 (4–5) 5 (4–6)#
HRQoL PhH 8 (3.5–9.5) 6 (3–9) 6 (4–7) 2 (2–2) 11 (11–11) 15 (15–15) 4 (1.5–7) 5 (3–8)* 0 (0–0)#
HRQoL PsH 3 (1–5) 0 (0–1) 3 (1–5) 2 (2–2) 10 (10–10) 15 (15–15) 0.5 (0–2.5) 2 (0–5)* 0 (0–0)#
HRQoL total 
score
9 (4–16.5) 8 (3–10) 9 (7–10) 4 (4–4) 21 (21–21) 30 (30–30) 5.5 (2–9) 8 (4–10)* 0 (0–0)#
Pain/swell. in > 1 
joint
20 (100%) 10 (100%) 24 (100%) 2 (100%) 2 (100%) 2 (100%) 38 (95%) 98 (98%) 0 (0%)#
Morning stiff-
ness > 15 min
4 (20%) 0 (0%) 6 (25%) 0 (0%) 0 (0%) 0 (0%) 5 (12.5%) 15 (15%) 0 (0%)*
Subjective remis-
sion
17 (85%) 8 (80%) 22 (91.7%) 2 (100%) 2 (100%) 2 (100%) 34 (85%) 87 (87%)
In treatment 20 (100%) 10 (100%) 18 (75%) 2 (100%) 0 (0%) 2 (100%) 38 (95%) 90 (90%)*
Reporting side 
effects
8 (40%) 4 (40%) 9/18 (50%) 0 (0%) – 2 (100%) 7/38 (18.4%) 30/90 (33.3%)
Taking medication 
regularly
18 (90%) 10 (100%) 16/18 (88.9%) 2 (100%) – 1 (50%) 38/38 (100%) 85 (94.4%)
With problems 
attending school
2/4 (50%) 2/4 (50%) 6/6 (100%) – – – 5/15 (33.3%) 15/29 (51.7%) 0 (0%)#
Satisfied with dis-
ease outcome
1 (5%) 3 (30%) 5 (20.8%) 0 (0%) 0 (0%) 0 (0%) 11 (27.5%) 20 (20%)
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PF items, with the exception of PF item 14, and for 90% of 
the HRQoL items, with the exception of HRQoL item 10.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 14) and 100% of items of the 
HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.86 for PF-LL, 0.86 for PF-HW, 
0.77 for PF-US. Cronbach’s alpha was 0.77 for HRQoL 
PhH and 0.85 for HRQoL PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/156 Child N = 16/60
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 68.0% 87.5%
 HRQoL PhH 31.0% 12.5%
 HRQoL PsH 59.0% 0.0%
 Pain VAS 8.0% 0.0%
 Disease activity VAS 4.0% 6.2%
 Well-being VAS 0.0% 0.0%
Ceiling effect, median
 PF 6.0% 0.0%
 HRQoL PhH 11.0% 0.0%
 HRQoL PsH 7.0% 56.3%
 Pain VAS 9.0% 6.2%
 Disease activity VAS 7.0% 0.0%
 Well-being VAS 6.0% 6.2%
Items with equivalent item–scale correlation 93% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Items with items–scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 67% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.86 0.79
 PF-HW 0.86 0.56
 PF-US 0.77 0.57
 HRQoL PhH 0.77 0.62
 HRQoL PsH 0.85 0.80
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.99
 HRQoL PhH 0.95 1.0
 HRQoL PsH 1.0 0.82
Spearman correlation with JIA core set variables, median
 PF 0.4 − 0.2
 HRQoL PhH 0.4 − 0.03
 HRQoL PsH 0.3 − 0.1
 Pain VAS 0.3 0.2
 Disease activity VAS 0.4 0.2
 Well-being VAS 0.5 0.5
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in ten JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 7 days (7–7 days). The intraclass corre-
lation coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 1.0). The ICC for the 
HRQoL PhH and for the HRQoL PsH scores showed an 
almost perfect reproducibility (ICC = 0.95 and ICC = 1.0, 
respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.4 
(median = 0.4). The PF total score best correlation was 
observed with the physician global assessment of well-
being (r = 0.4, p < 0.001). For the HRQoL, the median 
correlation of the PhH with the JIA core set of outcome 
variables ranged from 0.3 to 0.5 (median = 0.4), whereas 
for the PsH ranged from 0.2 to 0.4 (median = 0.3). The 
PhH and the PsH showed the best correlation with the phy-
sician global assessment of well-being (r = 0.5, p < 0.001 
and r = 0.4, p < 0.001, respectively). The median corre-
lations between the pain VAS, the well-being VAS, and 
the disease activity VAS and the physician-centered and 
laboratory measures were 0.3 (0.2–0.5), 0.4 (0.4–0.5), 0.5 
(0.4–0.6), respectively.
Discussion
In this study, the Egyptian Arabic version of the JAMAR 
was fully cross-culturally adapted from the original standard 
English version with two forward and two backward transla-
tions. According to the results of the validation analysis, the 
Egyptian Arabic parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: one PF item (“bend 
head back and look at the ceiling”) showed a lower item’s 
internal consistency. However, the overall internal consist-
ency was good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The statistical performances of the child version of the 
JAMAR are very similar, although slightly poorer, to those 
obtained for by the parent version, which suggests that chil-
dren are reliable reporters of their disease and health status.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other dimen-
sions of daily life that were not previously considered by 
other HRQoL tools. This may provide useful information 
for intervention and follow-up in health care.
In conclusion, the Egyptian Arabic version of the 
JAMAR was found to have satisfactory psychometric 
properties and it is, thus, a reliable and valid tool for the 
multidimensional assessment of children with JIA.
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